| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfae81468523c4a7e635145a1bfe2359 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7069 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate |
2003-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ee0befd585e5af5e982757ff26f17f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1db7598133c6d25dc699caedd8f24997 |
| publicationDate |
2007-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2301063-C9 |
| titleOfInvention |
Formulation for transepicutan administration in treatment of restless legs syndrome |
| abstract |
FIELD: medicine, pharmacy. n SUBSTANCE: invention relates to a transepicutan pharmaceutical composition that contains rotigotin and used in effective treatment of the restless legs syndrome (RLS), especially in form of transdermal therapeutic system based on acrylate or silicon having surface 2.5-20 cm 2 and containing rotigotin in the concentration 1.125-9.0 mg/cm 2 as an active component against restless less syndrome. The composition improves state of patients suffering from restless legs syndrome as compared with treatment with placebo by 2 units or more according assessment scale of International investigation group of restless legs syndrome (IRLSSG) after administration of the composition for at least 8 days. n EFFECT: valuable property and enhanced effectiveness of formulation. n 20 cl, 1 tbl, 4 ex |
| priorityDate |
2002-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |